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Abstract.
Background:Quality of Life (QoL) is an important outcome measure in dementia, particularly in the context of interventions.
Research investigating longitudinal QoL in dementia with Lewy bodies (DLB) is currently lacking.
Objective: To investigate determinants and trajectories of QoL in DLB compared to Alzheimer’s disease (AD) and controls.
Methods: QoL was assessed annually in 138 individuals, using the EQ5D-utility-score (0–100) and the health-related Visual
Analogue Scale (VAS, 0–100). Twenty-nine DLB patients (age 69 ± 6), 68 AD patients (age 70 ± 6), and 41 controls (age
70 ± 5) were selected from the Dutch Parelsnoer Institute-Neurodegenerative diseases and Amsterdam Dementia Cohort. We
examined clinical work-up over time as determinants of QoL, including cognitive tests, neuropsychiatric inventory, Geriatric
Depression Scale (GDS), and disability assessment of dementia (DAD).
Results: Mixed models showed lower baseline VAS-scores in DLB compared to AD and controls (AD: ±SE = -7.6 ± 2.8,
controls: ±SE = -7.9 ± 3.0, p < 0.05). An interaction between diagnosis and time since diagnosis indicated steeper decline
on VAS-scores for AD patients compared to DLB patients (±SE = 2.9 ± 1.5, p < 0.1). EQ5D-utility-scores over time did not
differ between groups. Higher GDS and lower DAD-scores were independently associated with lower QoL in dementia patients
(GDS: VAS ±SE = -1.8 ± 0.3, EQ5D-utility ±SE = -3.7 ± 0.4; DAD: VAS = 0.1 ± 0.0, EQ5D-utility ±SE = 0.1 ± 0.1,
p < 0.05). No associations between cognitive tests and QoL remained in the multivariate model.
Conclusion: QoL is lower in DLB, while in AD QoL shows steeper decline as the disease advances. Our results indicate that
non-cognitive symptoms, more than cognitive symptoms, are highly relevant as they impact QoL.
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INTRODUCTION
Dementia with Lewy bodies (DLB) is the second
most common form of neurodegenerative dementia
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after Alzheimer’s disease (AD) in older people,
accounting for 4–10% of all dementia cases [1–3].
DLB is clinically characterized by cognitive decline
and one or more core features including fluctuat-
ing attention, visual hallucinations, parkinsonism and
rapid eye movement (REM) sleep behavior disorder
(RBD) [4]. DLB differs in clinical manifestation from
AD with more frequent non-cognitive symptoms,
including motor symptoms, autonomic dysfunction
and neuropsychiatric symptoms like delusions, apa-
thy, anxiety, and depression. DLB is associated with
earlier nursing home admission [5], decreased time
to death [6, 7], higher healthcare costs [5], and higher
caregiver burden [8, 9] compared to AD.
Quality of Life (QoL) is an important outcome
measure in dementia, especially when evaluating
the efficacy of interventions. Health-related QoL in
dementia is a multidimensional concept that includes
perceived mental, physical, emotional, and social
functioning in relation to different stages of a disease
[10]. When providing treatment in dementia care, the
ultimate goal is to optimize patients’ health-related
QoL. Knowledge on the natural trajectory of QoL
and determinants thereof is essential as this provides
a baseline condition for intervention studies, but also
enables the identification of potential targets for inter-
ventions aiming to optimize QoL.
To date, little is known about QoL in different types
of dementia and factors that determine QoL. Reviews
concerning QoL in dementia suggest that loss of func-
tional ability, limited social engagement [11] and
poorer mental and physical health [12] are associated
with worse QoL, while more severe cognitive impair-
ment does not seem to predispose for worse QoL [11].
These determinants are similar to those found in non-
demented older people [13]. Concerning longitudinal
QoL in dementia, some studies suggest that decline in
QoL over time is associated with the presence of neu-
ropsychiatric symptoms [12, 14–17], while another
study only found this effect when QoL was care-
giver reported [18]. However, these studies mainly
considered QoL in AD and used nursing home pop-
ulations, i.e., late disease stages. For DLB, one study
found that QoL was lower in DLB than in AD, and
that this was associated with the presence of neu-
ropsychiatric symptoms [19]. However, this study
was limited by a small sample size and cross-sectional
design. We hypothesized that QoL would decline
faster over time in DLB than in AD, related to more
prominent involvement of non-cognitive symptoms
in DLB. To test this hypothesis, the current multi-
center study aimed to investigate determinants and
trajectories over time of QoL in DLB, compared to
AD and controls.
METHODS
Patient groups
In this multicenter study, we included 140 patients
from the Dutch Parelsnoer Institute (PSI) Neu-
rodegenerative Diseases (n = 110) [20, 21], and the
Amsterdam Dementia Cohort (ADC; n = 30) [22].
PSI is an ongoing collaboration of eight university
medical centers in the Netherlands, in which data
are prospectively and uniformly collected. Patients
in PSI-neurodegenerative diseases were referred to
one of the eight Dutch academic memory clinics for
the evaluation of cognitive problems. The ADC is
based on data from the Alzheimer Center Amster-
dam, which is one of the eight memory clinics that
contributes to the PSI cohort and thus follows a sim-
ilar protocol as PSI-neurodegenerative diseases. For
this study, the ADC provided an additional sample of
subjects that were not included in the PSI cohort.
All patients received standardized work-up includ-
ing clinical data, cognitive assessment, MRI, blood
samples and CSF samples (optional) [20]. Syndrome
diagnoses were made in multidisciplinary meetings;
and included subjective cognitive decline (SCD),
mild cognitive impairment (MCI), or dementia. In
case of dementia, an etiological diagnosis was made.
For probable DLB, etiological diagnoses were made
according to the 2005 international consensus criteria
[23], for AD the National Institute of Neurological
and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Asso-
ciation (NINCDS-ADRDA) criteria were used [24].
All patients were invited annually for follow-up for
at least two years. In both cohorts, follow-up visits
consisted of neuropsychological assessment, clinical
questionnaires, and clinical assessment. Total follow-
up duration varied per patient, the median number of
visits was 3, with a minimum of 1 visit and a maxi-
mum of 6 visits. Mean follow-up time was 2.5 ± 1.8
years.
Patients were eligible for inclusion if QoL data
were available. From the PSI cohort, we included
all 19 patients with probable DLB. We matched
58 patients with AD and 33 controls with SCD on
age range and sex. From the ADC, we additionally
included all DLB patients with available QoL data
(n = 10) [22]. We matched these for age and sex with
10 AD patients and 10 SCD patients.
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The PSI-neurodegenerative diseases cohort and
ADC are approved by the Medical Ethics Review
Committee of the Amsterdam University Medical
Center. The research is performed according to the
principles of the Declaration of Helsinki. All patients
enrolled in the study gave their written informed con-
sent.
Instruments
Quality of Life
QoL was assessed with the Euro Quality of Life-5
dimensions (EQ5D) [25]. The EQ5D consists of five
questions and a health-related visual analogue scale
(VAS). In these questions, the respondent is asked
to rate their current health state on five dimensions
(mobility, hygiene, usual activities, pain/discomfort,
and anxiety/depression) into one of three levels (no
problems (1), some problems (2) or a lot of prob-
lems (3)). The answers are transformed into a utility
value, describing the respondent’s health, where util-
ity = 0 equals death and utility = 1 equals perfect
health. For example, the answer pattern 11111 would
result in perfect health state (utility = 1), whereas
33333 would result in the worst possible health state
(utility < 0, worse than death). The weights of the dif-
ferent answer patterns are based on the valuation of
these health states by the Dutch population, making
these scores useful in cost-utility analyses, health-
economics and medication trials.
In contrast, the VAS reflects the self-perceived
health-related QoL. Using the VAS, the respondents
rate their own health status on a 20-cm health ther-
mometer, which is recoded as a score between 0
(worst imaginable health state) to 100% (best imag-
inably health state) [25].
Non-cognitive symptoms
DLB core criteria were assessed for DLB patients
only during the clinical assessment at baseline. Core
criteria of DLB, i.e., visual hallucinations, parkin-
sonism, fluctuations, and RBD were rated as being
present or absent. Neuropsychiatric symptoms were
assessed with the 12 items Neuropsychiatric Inven-
tory, with information provided by the caregiver [26].
We recoded the neuropsychiatric symptoms as being
present (≥1) or absent. The Disability Assessment
for Dementia (DAD) is administered through an
informant-based interview for measuring the com-
petence in instrumental activities in daily living
((I)ADL), with scores ranging from 0 to 100%, higher
scores indicating higher competence [27]. Depressive
symptoms were assessed with the self-reported Geri-
atric Depression Scale (GDS), with scores ranging
from 0 to 15, higher scores indicating more depressive
symptoms [28].
Cognition
We used the Mini-Mental State examination
(MMSE) to assess global cognition [29]. Memory
functioning was assessed with the Dutch version of
the Auditory Verbal Learning test (AVLT). We used
the summed score of direct recall after 5 presen-
tations. The delayed recall was assessed after 20
minutes. Speed and attention were assessed with the
Trail Making Test-A (TMT-A), and Trail Making
Test-B (TMT-B) was used as a measure for executive
functioning.
Statistical analysis
Analyses were performed in SPSS (IBM®, V22,
Chicago, IL) and R (version 3.2.5, R Development
Core Team, 2010). After data check, we identified
and removed two outliers from the control group (>3
SD on baseline VAS). Hence, all analyses were con-
ducted on 29 DLB patients, 68 AD patients, and 41
controls. EQ5D-utility scores were multiplied by 100,
so that EQ5D-utility ranges between 0 and 100. Mul-
tiple imputation was used to impute missing values
of individual neuropsychological test-scores. Fifteen
imputed datasets were created to ensure stability
of the results. Analyses were done on the pooled
datasets. For TMT-A and TMT-B, inverted data were
used such that lower scores represent worse perfor-
mance. We log-transformed TMT-data to meet the
assumption of normally distributed data. ANOVA,
Kruskal-Wallis, and χ2 tests were used to test for
differences in demographics between DLB, AD, and
controls at baseline. Linear mixed models (LMM)
were used to compare QoL trajectories (EQ5D-utility
and VAS as dependent variables in separate mod-
els) between groups. The models included time since
diagnosis (years), diagnosis (categorical variable,
DLB as reference), and interaction of time and diag-
nosis as independent variables. The model included a
random intercept and a random slope. Main effect of
diagnosis represents the association between diagno-
sis and QoL at baseline. The interaction term between
time and diagnosis represents the association between
diagnosis and annual change in QoL. The analyses
were conducted with adjustment for age and sex.
To assess possible determinants of QoL in demen-
tia (DLB and AD; controls were not included in
392 M. van de Beek et al. / Quality of Life in DLB and AD
this analysis), we used LMM with baseline demo-
graphic variables, diagnosis, baseline and follow-up
data from the NPI subscales (0–1), GDS (0–15), DAD
(0–100), and cognitive test scores (MMSE, AVLT,
TMT-A, and TMT-B) as independent variables and
all available VAS and EQ5D-utility scores as depen-
dent variables. Of note, we used all available data,
baseline and follow-up, taking into account correla-
tions within persons. We first constructed univariate
models for each of the putative determinants and
for both outcome measures. Subsequently, we con-
structed a multivariate model, based on significant
determinants of the univariate models only (manual
backwards selection, with diagnosis added as covari-
ate). For main effects, significance level was set at
p < 0.05, for interaction effects at p < 0.10.
RESULTS
Demographic and clinical data are presented in
Table 1. MMSE and AVLT scores at baseline were
lower for the DLB and AD groups compared to
controls (p < 0.001). TMT-A and TMT-B scores
were lower in DLB compared to AD and con-
trols (AD: p < 0.05, controls: p < 0.001). AD patients
scored lower on TMT-A and TMT-B scores com-
pared to controls as well (p < 0.001). Furthermore,
patients with DLB had lower DAD scores than con-
trols (p < 0.001). In line with diagnostic criteria,
caregivers more frequently reported hallucinations
and apathy in DLB patients compared to controls
(p < 0.05, Fig. 1). At baseline, 14% of DLB patients
and 27% of AD patients were using cholinesterase
inhibitors.
Linear mixed models showed that baseline QoL
measured with the VAS was lower in DLB com-
pared to AD and controls (AD: ±SE = -7.6 ± 2.8,
controls: ±SE = -7.9 ± 3.0, both p < 0.05) (Table 2
and Fig. 2A). In addition, we found an interaction
between diagnosis and time, indicating that patients
with AD had a steeper decline over time than DLB
(±SE = 2.9 ± 1.5, p < 0.10). QoL in DLB patients
remained stable (Fig. 2A).
Table 1
Baseline characteristics
n DLB n AD n Controls
Sex, n female (%)1 29 2 (6.9%) 68 2 (2.9%) 41 2 (4.9%)
Age1, mean ± SD 29 69.0 ± 6.3 68 70.4 ± 6.1 41 69.8 ± 5.3
Years of education, mean ± SD 29 11 ± 3 68 11 ± 4 41 11 ± 3
Follow-up time, mean ± SD 29 2.1 ± 1.9 68 2.5 ± 1.9 41 2.9 ± 1.8
On CHEI, n (%) 29 4 (13.8%)a 68 18 (26.5%)a 41 0
DAD, median [range] 27 79 [31–100]a 68 81 [31–100]a 41 95 [33–100)
GDS, median [range] 28 3 [1–11] 68 2 [0–11] 41 2 [0–10]
NPI, median [range] 29 16 [0–69] 68 11 [0–75] 41 6 [0–61]
Cognitive tests, median [IQR]
MMSE 28 25 [22–27]a 68 25 [22–27]a 41 29 [25–30]
AVLT - 5 trials summed# 28 23 [17–30]a 68 22 [15–28]a 41 36 [30–44]
AVLT - delayed recall# 28 4 [1–6]a 68 2 [0–4]a 41 6 [5–8]
Trail Making Test A – time# 28 91 [68–119]a,b 68 61 [46–80]a 41 39 [35–51]
Trail Making Test B – time# 28 324 [230–480]a,b 68 188 [139–280]a 41 88 [76–111]
DLB symptoms, n(%)
Fluctuations 24 18 (75%)
Visual hallucinations 24 15 (63%)
Parkinsonism 24 16 (67%)
RBD 17 10 (59%)
Quality of Life, median [IQR]
VAS 27 70 [61–80]b 68 80 [70–90] 41 80 [70–90]
EQ5D-utility 27 84 [72–90] 68 90 [77–100] 41 90 [80–100]
Mobility 9 (33%) 18 (27%) 17 (22%)
Self-care 3 (11%) 5 (7%) 0
Usual activities 9 (33%) 17 (25%) 6 (15%)
Pain/discomfort 12 (44%) 23 (34%) 17 (42%)
Anxiety/depression 8 (30%) 18 (27%) 6 (15%)
DLB, dementia with Lewy bodies; AD, Alzheimer’s disease; MMSE, Mini-Mental State Examination; CHEI,
cholinesterase inhibitor; DAD, Disability Assessment for Dementia; GDS, Geriatric Depression Scale; NPI, Neuropsy-
chiatric Inventory; AVLT, Auditory Verbal Learning Test, RBD, REM sleep behavior disorder. ap≤ 0.05 compared to
controls, bp≤ 0.05 compared to AD. 1Matched variables. #Imputed data. Percentage of missing values before imputation:
ALVT-direct recall: 1.5%, ALVT-delayed recall: 1.5%, TMT-A: 1.5%, TMT-B: 15.3%.
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For QoL measured with EQ5D-utility, we found
that DLB had lower QoL at baseline compared to
controls (±SE = -9.2 ± 4.1, p < 0.05). There was
no significant difference in course of EQ5D-utility
scores over time between groups (Table 2 and
Fig. 2B). Analysis of the five separate questions of
the EQ5D revealed no significant differences between
groups on either the mobility, self-care, usual activ-
ities, pain/discomfort or depression/anxiety question
(Table 1).
Fig. 1. The prevalence of Neuropsychiatric Inventory (NPI) symp-
toms in dementia with Lewy bodies (DLB, n = 29), Alzheimer’s
disease (AD, n = 68), and controls (n = 41) at baseline. ∗p < 0.05,
χ2 test.
Subsequently, to assess possible determinants for
QoL in dementia, we used linear mixed mod-
els. Table 3 shows the associations of different
demographics at baseline, neuropsychiatric symp-
toms, and cognitive tests scores with QoL in terms
of VAS and EQ5D. For VAS scores we found
an association with diagnosis, as DLB had lower
VAS scores compared to AD (±SE = 5.1 ± 2.4,
p < 0.05). Furthermore, higher scores on the GDS
and lower scores on the DAD were associated with
lower VAS score (GDS±SE = -1.9 ± 0.3, p < 0.001;
DAD ±SE = 0.1 ± 0.0, p < 0.05). In addition, lower
TMT-A scores were associated with lower VAS
scores (±SE = 3.4 ± 1.6, p < 0.05). Subsequently,
we constructed a multivariate model using back-
wards selection, controlling for diagnosis. GDS
and DAD scores remained as independent deter-
minants (GDS ±SE = -1.8 ± 0.3, p < 0.001; DAD
±SE = 0.1 ± 0.0, p < 0.05).
Lower scores for EQ5D-utility were related
with higher scores on the GDS and lower
scores on the DAD (GDS ±SE = -3.7 ± 0.4,
p < 0.001; DAD±SE = 0.2 ± 0.1, p < 0.05). Further-
more, presence of depression and anxiety on NPI
were associated with lower EQ5D-utility (depres-
sion ±SE = -5.6 ± 2.5, p < 0.05; anxiety ±SE = -
5.4 ± 2.6, p < 0.05). In a multivariate model with
backwards selection, both GDS and DAD remained
independent determinants of EQ5D-utility (GDS
±SE = -3.7 ± .4, p < 0.001; DAD±SE = 0.1 ± 0.1,
p < 0.05). When stratifying the data for diagnosis,
comparable results were found in AD and DLB sep-
arately (data not shown).
DISCUSSION
The main finding of this multicenter study is that
QoL at the time of diagnosis was lower in DLB
patients than in AD patients, while subsequently QoL
in AD patients declined more steeply over time and
Table 2
Dementia types and trajectories in QoL
VAS EQ5D-utility
Baseline effect Change over time Baseline effect Change over time
DLB versus AD –7.55 (2.79)∗ 2.85 (1.54)+ –5.40 (3.80) 1.26 (2.11)
DLB versus controls –7.94 (3.02)∗ 1.77 (1.61) –9.16 (4.11)* 2.95 (2.23)
Data represent  (SE). Linear mixed models were used include term for time and diagnosis, the interaction term
for time ∗ diagnosis was used to estimate change of over time between diagnosis for VAS and EQ5D-utility scores,
corrected for age and sex. Negative betas indicate lower scores at baseline for DLB compared to AD/controls
or steeper decline over time for DLB compared to AD/controls. ∗p≤ 0.05, +p≤ 0.1. DLB, dementia with Lewy
bodies; AD: Alzheimer’s disease.
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Fig. 2. Estimated trajectories of QoL over time for patients with DLB, AD, and controls. Data represent individual trajectories of raw QoL-
scores over time. Regression lines represent estimated group trajectories over time in years with 95% confidence intervals. A) Trajectories
of Visual Analogue Scale (VAS) over time. B) Trajectories of EQ5D-utility scores over time.
Table 3
Mixed models associations with VAS and EQ5D-utility
VAS EQ5D-utility
Model 1 Model 2 Model 1 Model 2
Diagnosis, AD versus DLB 5.06 (2.37)∗ 5.86 (3.71)
Sex, female versus male –1.46 (5.95) –3.11 (8.80)
Age, years 0.24 (0.17) -0.07 (0.26)
MMSE 0.07 (0.19) 0.06 (0.27)
GDS –1.85 (0.30)∗ –1.79 (0.32)∗ –3.71 (0.42)∗ –3.67 (0.42)∗
DAD 0.12 (0.04)∗ 0.10(0.04)* 0.15 (0.06)* 0.14 (0.06)∗
AVLT - direct recall# –0.03 (0.08) 0.14 (1.25)
AVLT - delayed recall# –0.51 (0.36) –0.01 (0.55)
Trail Making Test – A# 3.38 (1.62)∗ 1.74 (2.29)
Trail Making Test – B# 0.34 (1.73) 2.25 (2.57)
NPI subscales
Delusions –1.77 (2.76) –0.66 (3.98)
Hallucinations –2.98 (2.48) –0.16 (3.57)
Agitation 1.99 (1.83) 1.29 (2.61)
Depression –0.34 (1.78) –5.63 (2.50)∗
Anxiety –2.20 (1.84) –5.37 (2.60)∗
Euphoria 2.34 (2.60) 0.40 (3.68)
Apathy –1.78 (1.74) –0.42 (2.48)
Disinhibition 3.50 (2.13) –0.21 (3.07)
Irritability –0.43 (1.76) –3.34 (2.51)
Aberrant motor behavior 0.97 (2.09) –2.43 (2.98)
Sleep disturbances –0.87 (1.86) –0.02 (2.65)
Eating disturbances 1.09 (1.88) –1.04 (2.66)
Data represent  (SE). Linear mixed models include putative determinants as independent variables and VAS
and EQ5D-utility as outcome variable. Model 1: univariate associations with VAS and EQ5D-utility. Model 2:
associations with VAS and EQ5D after backwards selection. MMSE, Mini-Mental State Examination; DAD,
Disability Assessment for Dementia; GDS, Geriatric Depression Scale; NPI, Neuropsychiatric Inventory; AVLT,
Auditory Verbal Learning Test. ∗p≤ 0.05. #Missing values are imputed with multiple imputation, analyses are
done on fifteen pooled datasets, percentage of missing values before imputation: ALVT-direct recall: 4.5%, ALVT-
delayed recall: 4.8%, TMT-A: 3.1%, TMT-B: 25%.
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DLB patients remained relatively stable. In addition,
we found that independent of type of dementia, higher
reports of depressive symptoms and higher depen-
dency in (I)ADL were associated with lower QoL,
while severity of cognitive impairment was not asso-
ciated with lower QoL.
At baseline, QoL in DLB patients was lower than
in AD patients. Contrary to our hypothesis, however,
QoL in DLB remained relatively stable on follow-
up, while we observed marked decline in QoL as
measured by VAS in AD. Previous studies on lon-
gitudinal QoL in dementia have been inconclusive.
While some studies report no change in QoL after
one-year follow-up [30, 31], others found only a
decrease in relation with neuropsychiatric symptoms
[18]. Patients with DLB present with a wide variety
of non-cognitive symptoms, such as motor impair-
ment, neuropsychiatric symptoms, and autonomic
dysfunction [4]. We suspect that our findings could be
explained by the fact that these symptoms are present
early in DLB, therefore explaining the lower QoL at
baseline. It is conceivable that non-cognitive symp-
toms play an increasingly large role in AD in the
course of the disease, resulting in a decline in QoL as
AD advances [18, 32].
In line with this hypothesis and previous research,
we found an association between non-cognitive
symptoms and QoL, as functional impairment and
depressive symptoms were related to lower QoL.
Also, we found that severity of cognitive impairment
was not independently related to QoL. To put this in
a broader perspective, non-cognitive symptoms like
depressive symptoms and loss of functional ability
are not only associated with lower QoL, other stud-
ies have linked these symptoms to higher caregiver
burden [33, 34] and earlier nursing home admission
[35–38] as well. Taken together, this illustrates that
non-cognitive symptoms, more than cognitive symp-
toms are highly relevant as they have impact on the
experienced QoL and disease burden of patients with
dementia.
Differences in trajectories of QoL between diag-
nostic groups were only found when QoL was
measured with the VAS score. The EQ5D-utility
scores show a similar trend as the VAS, yet these
differences did not reach significance. A potential
explanation for this finding is the distribution of
EQ5D-utility scores. When all five questions of the
EQ5D are answered negatively, the score automati-
cally reaches maximum. Therefore, the utility-score
shows a ceiling effect, making the statistical analyses
less powerful and easy to interpret. In contrast, the
VAS score is normally distributed and is based on a
more subjective rating of QoL.
Strengths of the current study include the multicen-
ter approach and the longitudinal design. All patients
were diagnosed following a standardized diagnos-
tic protocol which was harmonized across centers.
Using data from multiple centers, contributes to the
generalizability of our study. Furthermore, our iden-
tified determinants of QoL were assessed over the
course of the disease, so it takes into consideration
the QoL of patients with dementia at several points
in time. We had a mean follow-up duration of around
2.5 years, which is considerably longer than many
other recent studies investigating longitudinal QoL
[14, 30]. By using a longitudinal design, we can
draw conclusions about naturalistic disease course.
Furthermore, our study has more power compared
to a cross-sectional design, as we consider multi-
ple data points per participant. Among the potential
limitations is that not all patients that were included
at baseline had sufficient follow-up data available.
Patients that were lost to follow-up had lower MMSE
scores at time of diagnosis and it is likely that they
were in a more advanced disease stage at the time of
diagnosis. The selection toward cognitively health-
ier patients at follow-up may give a more favorable
image of the course of QoL over time. Second,
it could be argued that there is considerable over-
lap between the concepts of depressive symptoms
and QoL. Patients that score high on the GDS are
likely to have a higher score on the EQ5D depres-
sion/anxiety question as well. Therefore, presence
of depressive symptoms lowers the EQ5D-utility
score. However, we found the same relation with
depressive symptoms for the VAS score, which is
not directly targeted at measuring depression. Since
comparable results are found in both measures, we
believe that depressive symptoms are a robust deter-
minant of QoL, but a certain degree of circularity
is inevitable. Third, our research focused on QoL
in DLB and AD, but did not include other types
of dementia like vascular dementia or frontotem-
poral dementia, nor did we take the possibility of
mixed pathology into account. However, we found
that non-cognitive symptoms are the main determi-
nant of QoL, irrespective of type of dementia. We
suspect that in cases with mixed pathology and other
types of dementia, the same non-cognitive symp-
toms will influence QoL. In line with this notion,
previous studies on QoL in for example vascu-
lar dementia found the same determinants of QoL
[39, 40]. Finally, our control group consisted of
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individuals with SCD. These patients experience
memory decline, but perform within normal range
on cognitive tests. Previous research has found that
in individuals with SCD, higher reports of cogni-
tive complaints are related with worse QoL in SCD
[41]. It is possible that the results would have been
different if we used a control group without cogni-
tive complaints, and that our current results reflect an
underestimation of the effect.
This study has important clinical implications.
First, our results underline the importance of prevent-
ing and treating depressive symptoms in dementia.
Clinicians need to be aware of the relevance of
these symptoms and adequately address them over
the course of the disease in order to maintain QoL.
Furthermore, our results might imply that interven-
tions aiming to maintain independency in daily living
may help to optimize QoL. This could be via psy-
chosocial interventions that target independency, as
well as pharmacological interventions. For exam-
ple, one study investigating the effect of memantine
in DLB found that improved physical health gener-
ally improved the perceived QoL [42]. Thus, in the
search of disease modifying treatment for dementia,
the focus should not merely be on preserving cogni-
tion, but also preserving autonomy. As the ultimate
goal with any intervention is to maintain or improve
QoL, future interventions should also target non-
cognitive symptoms like depression and dependency
in (I)ADL.
In conclusion, we found different trajectories of
QoL in DLB compared to AD, as patients with DLB
initially present with lower QoL, while AD patients
show steeper decline in QoL over time. Future
interventions aimed at optimizing QoL in dementia
should focus on decreasing depressive symptoms and
maintaining independence, as these are major deter-
minants of QoL in dementia.
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